Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peripheral Artery Disease

Peripheral Artery Disease

Part of Atherosclerosis

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peripheral Artery Disease

60 trials tracked for Peripheral Artery Disease: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 83 citations.

60Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 7 Phase 2 7 Phase 1 1 Other / NA 44
  1. Phase 3 RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty Completed · 83 cited
  2. Phase 3 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities Completed · 19 cited
  3. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 16 cited
  4. Phase 3 Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes Completed · 13 cited
  5. Phase 3 Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease Completed · 2 cited
  6. Phase 4 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Completed
Show 44 more trials
  1. Phase 3 Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure Completed
  2. Phase 3 CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings Completed
  3. Phase 2 Unacylated Ghrelin to Improve Functioning in PAD Completed
  4. Phase 2 Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial Completed
  5. Phase 2 Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents Completed
  6. Phase 2 Patients With Intermittent Claudication Injected With ALDH Bright Cells Completed
  7. Phase 2 Hepatocyte Growth Factor to Improve Functioning in PAD Completed
  8. Phase 2 Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD Completed
  9. Phase 2 Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH) Completed
  10. Phase 1 Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA) Completed
  11. N/A Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE) Completed
  12. N/A Comprehensive Magnetic Resonance of Peripheral Arterial Disease Completed
  13. N/A LEVANT 2 Safety Registry Completed
  14. N/A Leg Thermotherapy for Intermittent Claudication Completed
  15. N/A Cocoa to Improve Walking Performance in Peripheral Artery Disease Completed
  16. N/A In-Stent Restenosis Post-Approval Study Completed
  17. N/A Safety and Effectiveness Evaluation of Peripheral Orbital Atherectomy Completed
  18. N/A ILLUMENATE Pivotal Post-Approval Study (PAS) Completed
  19. N/A Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease Completed
  20. N/A Safety and Efficacy of the SurVeil™ Drug-Coated Balloon Completed
  21. N/A Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries Completed
  22. N/A LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB) Completed
  23. N/A Framing Clinical Trial Enrollment for Patients With Peripheral Artery Disease Completed
  24. N/A Platelet Activity in Vascular Surgery and Cardiovascular Events Completed
  25. N/A Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients Completed
  26. N/A TEsting for Arterial Disease in Diabetes (TrEAD) Study Completed
  27. N/A Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System Completed
  28. N/A Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease Completed
  29. N/A The Pathway PVD Study for Percutaneous Peripheral Vascular Interventions Completed
  30. N/A Assessment Of Vascular Health After Niacin Therapy (AVANT) Completed
  31. N/A Optical Imaging Measurement of Intravascular Solution Efficacy Trial Completed
  32. N/A Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease Completed
  33. N/A Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization Completed
  34. N/A Low InTensity Exercise Intervention in PAD Completed
  35. N/A BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease Completed
  36. N/A Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal Completed
  37. N/A Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease Completed
  38. N/A Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol Completed
  39. N/A Absolute Pro® MOMENTUM™ Completed
  40. N/A Evaluation of Imaging of Peripheral Arteries by Optical Coherence Tomography and Intravascular Ultrasound Imaging Completed
  41. N/A 3-year Follow-up of Patients Treated With Jetstream Combined With Ranger for Calcified Femoropopliteal Lesions Completed
  42. N/A Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound Completed
  43. N/A Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis Completed
  44. N/A Impacts of Aquatic vs Land Walking on Vascular Health and Exercise Tolerance in Patients With Peripheral Artery Disease Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Peripheral Artery Disease: what the trials found

In established trials, rivaroxaban (Xarelto) reduced the composite of myocardial infarction, ischemic stroke, cardiovascular death, acute limb ischemia, and major amputation compared to placebo (508 vs. 584 events, p=0.0043) 6. However, TIMI major bleeding was numerically higher but not statistically significant (62 vs. 44, p=0.0695) 6. Ticagrelor did not significantly reduce the composite of cardiovascular death, MI, or ischemic stroke (751 vs. 740, p=0.650) 7. Paclitaxel improved primary lesion patency (p=0.0017) but increased major adverse events (p<0.0001) 5. Nebivolol improved peak walking time (mean change 110.4 vs. -19.4 seconds, p=0.039) but not ankle-brachial index or claudication onset time 10. Nicotinamide riboside improved six-minute walk distance compared to placebo (p=0.0294), but the combination with resveratrol was not superior to NR alone 9. The CLiRpath Photoablation System achieved laser success (p=0.001) 11. Aspirin did not significantly change microvascular blood flow composite score 8. Dexamethasone infusion did not significantly change percent wall volume, wall volume, or inflammatory profile 4.

Physical activity improved self-reported physical function score (59.73 vs. 58.73, p<0.001) but did not reduce cardiovascular events (5231 vs. 5324, p=0.49) or non-cardiovascular mortality 2. Ghrelin did not significantly improve six-minute walk distance, maximal treadmill walking time, or calf muscle perfusion 1. Atherectomy outcomes were reported but without comparative p-values 3. Telemedicine specialty consultation was studied but results are not yet established 22.

Recent results — preliminary, needs further review

  • Ghrelin showed no significant improvement in six-minute walk distance, maximal treadmill walking time, or calf muscle perfusion at 4 months 1.
  • Physical activity improved self-reported physical function but did not reduce cardiovascular events or non-cardiovascular mortality 2.
  • Atherectomy outcomes were reported but require further validation 3.
  • Opt-out strategies and assistive tennis shoes are under investigation 1920.
  • Peripheral orbital atherectomy system achieved acute device success in 55% of subjects 21.

For the clinician treating this condition

  • Rivaroxaban reduces major ischemic events in PAD but with a non-significant increase in major bleeding; consider benefit-risk profile 6.
  • Paclitaxel improves patency but increases adverse events; use with caution 5.
  • Nebivolol improves walking distance and may be considered for symptom management 10.
  • Nicotinamide riboside improves walking distance; further study needed 9.

AI synthesis of 15 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios
Diabetes & Endocrinology Sys. Review
GLP-1 receptor agonists and tirzepatide provide cardiovascular benefits across multiple clinical scenarios Incretin Drugs Show Heart Benefits Across Multiple Conditions
This state-of-the-art review synthesizes evidence regarding incretin analogues, specifically GLP-1 receptor agonists and tirzepatide. The re…
GLP-1 drugs and tirzepatide prove heart benefits in diabetes, obesity, heart failure, and more.
Frontiers Jul 25, 2026
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD
Diabetes & Endocrinology Meta-analysis
GLP-1 receptor agonists reduce major adverse limb events with HR 0.59 in PAD New analysis shows GLP-1 drugs cut stroke risk for people with leg artery disease
This systematic review and meta-analysis of over 240,000 adults with peripheral artery disease found that GLP-1 receptor agonists significan…
A large review of real-world data found GLP-1 drugs significantly reduce stroke and heart attack risk in adults with peripheral artery disea…
Jun 1, 2026
Narrative review discusses screening and prevention in rheumatic and musculoskeletal disease populations
Cardiology Sys. Review
Narrative review discusses screening and prevention in rheumatic and musculoskeletal disease populations Joint Pain May Signal Hidden Risk in Your Legs
This narrative review examines patients with rheumatic and musculoskeletal diseases (RMDs), including rheumatoid arthritis and systemic lupu…
Inflammation from autoimmune conditions can silently damage blood vessels in your legs.
Frontiers Apr 23, 2026
GLP-1RAs associated with improved walking distance in diabetes with PAD, but limb event evidence uncertain
Nutrition & Obesity Medicine Meta-analysis
GLP-1RAs associated with improved walking distance in diabetes with PAD, but limb event evidence uncertain GLP-1 drugs linked to better walking distance in diabetes patients with leg artery disease
A meta-analysis of 7 studies (107,092 adults with type 2 diabetes and PAD) found GLP-1RAs were associated with improved walking distance in …
GLP-1 diabetes drugs linked to better walking distance in people with leg artery disease, based on analysis of seven studies involving over …
Apr 2, 2026

Questions about Peripheral Artery Disease

Do GLP-1 receptor agonists reduce limb complications for people diagnosed with Peripheral Artery Disease?

GLP-1 receptor agonists reduce major adverse limb events (MALE) and cardiovascular risks in people with type 2 diabetes and peripheral artery disease, based on meta-analyses.

Full answer →
What are the cardiovascular benefits of using incretin analogues in Peripheral Artery Disease?

Incretin analogues (GLP-1 RAs) reduce cardiovascular risk in PAD by improving walking distance, lowering inflammation, and decreasing heart attack and stroke events.

Full answer →
Do GLP-1RAs help improve walking distance for those with diabetes and Peripheral Artery Disease?

Yes, GLP-1 receptor agonists (liraglutide, semaglutide) improve walking distance in people with type 2 diabetes and peripheral artery disease, based on a 2025 meta-analysis of randomized trials.

Full answer →
Can tirzepatide provide cardiovascular benefits for people living with Peripheral Artery Disease?

Yes, tirzepatide may reduce major adverse limb events and cardiovascular risks in people with PAD, but direct trial data are still limited.

Full answer →
Do GLP-1 receptor agonists reduce major limb events for patients with Peripheral Artery Disease?

Yes, GLP-1 receptor agonists reduce major limb events in patients with type 2 diabetes and peripheral artery disease, with a 27% lower risk shown in a 2026 meta-analysis.

Full answer →
See all 5 questions about Peripheral Artery Disease →